RhumbLine Advisers’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-544
| Closed | -$54 | – | 4097 |
|
|
2025
Q4 | $54 | Hold |
544
| – | – | ﹤0.01% | 4100 |
|
|
2025
Q3 | $329 | Hold |
544
| – | – | ﹤0.01% | 4071 |
|
|
2025
Q2 | $169 | Sell |
544
-129,156
| -100% | -$50K | ﹤0.01% | 4097 |
|
|
2025
Q1 | $63.4K | Sell |
129,700
-4,635
| -3% | -$2.73K | ﹤0.01% | 3520 |
|
|
2024
Q4 | $115K | Buy |
134,335
+988
| +0.7% | +$6.19K | ﹤0.01% | 3441 |
|
|
2024
Q3 | $1.13M | Sell |
133,347
-548
| -0.4% | -$3.23K | ﹤0.01% | 2199 |
|
|
2024
Q2 | $625K | Buy |
133,895
+133,351
| +24,513% | +$631K | ﹤0.01% | 2513 |
|
|
2024
Q1 | $3.7K | Hold |
544
| – | – | ﹤0.01% | 4019 |
|
|
2023
Q4 | $1.82K | Hold |
544
| – | – | ﹤0.01% | 4105 |
|
|
2023
Q3 | $1.35K | Hold |
544
| – | – | ﹤0.01% | 4156 |
|
|
2023
Q2 | $696 | Buy |
+544
| New | +$722 | ﹤0.01% | 4303 |
|
|
2022
Q2 | – | Sell |
-17,409
| Closed | -$37K | – | 3099 |
|
|
2022
Q1 | $37K | Sell |
17,409
-706
| -4% | -$1.89K | ﹤0.01% | 2987 |
|
|
2021
Q4 | $162K | Sell |
18,115
-321
| -2% | -$4.21K | ﹤0.01% | 2878 |
|
|
2021
Q3 | $306K | Buy |
18,436
+825
| +5% | +$14.2K | ﹤0.01% | 2756 |
|
|
2021
Q2 | $366K | Buy |
17,611
+1,869
| +12% | +$35.4K | ﹤0.01% | 2707 |
|
|
2021
Q1 | $295K | Sell |
15,742
-160
| -1% | -$3.45K | ﹤0.01% | 2697 |
|
|
2020
Q4 | $350K | Buy |
15,902
+1,000
| +7% | +$20.8K | ﹤0.01% | 2602 |
|
|
2020
Q3 | $309K | Sell |
14,902
-1,490
| -9% | -$38.7K | ﹤0.01% | 2508 |
|
|
2020
Q2 | $593K | Buy |
16,392
+8,623
| +111% | +$361K | ﹤0.01% | 2270 |
|
|
2020
Q1 | $254K | Buy |
+7,769
| New | +$314K | ﹤0.01% | 2472 |
|
RhumbLine Advisers's APLT Position: Q1 2026 in Review
RhumbLine Advisers sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 544 shares — an estimated $54 sold.
RhumbLine Advisers first reported a position in APLT in Q1 2020 and held it in 20 quarters. The position peaked at $1.13M in Q3 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.
- RhumbLine Advisers reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
- RhumbLine Advisers sold 544 Applied Therapeutics shares in Q1 2026, an estimated $54.
- RhumbLine Advisers first reported a position in Applied Therapeutics in Q1 2020 and held it in 20 quarters.
- RhumbLine Advisers's Applied Therapeutics position peaked at $1.13M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.